Venkatapur Reddy, MD
Internal Medicine · Haleyville, ALNPI 1770678302
Payments from drug & device makers
Across 220 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Atricure, Inc.$2K
- GSK$688
- AbbVie$353
- Amgen$301
- AstraZeneca$230
- Lilly USA, LLC$196
- plus $1K from 29 others
What the payments were for
- Travel & lodging$2,05440%
- Food & beverage$2,93958%
- Education$451%
- Gifts$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Atricure, Inc. | 6 | $2,054 |
| GSK | 59 | $688 |
| AbbVie(2 entities) | 48 | $353 |
| Amgen | 16 | $301 |
| AstraZeneca | 14 | $230 |
| Lilly USA, LLC | 9 | $196 |
| Novo Nordisk | 12 | $180 |
| Abbott | 1 | $130 |
| Astellas Pharma US Inc | 7 | $111 |
| Boehringer Ingelheim | 6 | $91 |
| Bayer | 5 | $90 |
| Grifols USA, LLC | 5 | $88 |
| Tosoh Bioscience, Inc. | 1 | $54 |
| Eisai Inc. | 3 | $52 |
| Johnson & Johnson | 3 | $48 |
| Pfizer | 2 | $39 |
| Merck | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| Amarin Pharma, Inc. | 2 | $34 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Mylan Specialty L.p. | 2 | $25 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $19 |
| Vertex | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Gilead | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Bausch Health US, LLC | 1 | $16 |
| SK Life Science, Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,091 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 190 | $185,976 |
| EliquisApixaban | 215 | $156,542 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 153 | $130,391 |
| FarxigaDapagliflozin Propanediol | 161 | $123,875 |
| LinzessLinaclotide | 109 | $82,125 |
| JardianceEmpagliflozin | 100 | $77,983 |
| JanuviaSitagliptin Phosphate | 61 | $63,341 |
| XifaxanRifaximin | 16 | $55,319 |
| RexultiBrexpiprazole | 35 | $53,848 |
| EntrestoSacubitril/Valsartan | 59 | $44,305 |
| MounjaroTirzepatide | 34 | $39,445 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $30,059 |
| TrulicityDulaglutide | 22 | $26,190 |
| MyrbetriqMirabegron | 46 | $21,691 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $15,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $180 | $185,976190 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $230 | $164,699223 claims |
| PfizerEliquis | $39 | $156,542215 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $688 | $148,319200 claims |
| AbbVieLinzess | $353 | $82,125109 claims |
| Boehringer IngelheimJardiance | $91 | $77,983100 claims |
| Lilly USA, LLCMounjaro, Trulicity | $196 | $65,63456 claims |
| MerckJanuvia | $37 | $63,34161 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $13 | $53,84835 claims |
| Astellas Pharma US IncMyrbetriq | $111 | $21,69146 claims |
| Johnson & JohnsonXarelto | $48 | $10,77511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Haleyville
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.